Gardner Lewis Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Gardner Lewis Asset Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$2.64M	–	103
2026 Q1	$2.64M	Buy	+50,000	New	+$2.05M	0.57%	50

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Gardner Lewis Asset Management's TERN Position: Q2 2026 in Review

Gardner Lewis Asset Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 50,000 shares — an estimated $2.64M sold.

Gardner Lewis Asset Management first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $2.64M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Gardner Lewis Asset Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Gardner Lewis Asset Management sold 50,000 Terns Pharmaceuticals shares in Q2 2026, an estimated $2.64M.
Gardner Lewis Asset Management first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Gardner Lewis Asset Management's Terns Pharmaceuticals position peaked at $2.64M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Gardner Lewis Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.